According to other data, patients in the setting of newly diagnosed prostate cancer, can be divided in three different risk groups, low corresponds to zero risk factors, intermediate to one or to two risk factors and high corresponds with three risk factors depending on the changes of ALP, PSA and hemoglobin (Hb) under therapy predicting PFS and OS. The gene discussed is KLK3; the disease is prostate cancer.